Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial

BMJ

Volumn 311, Issue 7011, 1995, Pages 977-

  Mcdonald, carolyn C ^a,b   Alexander, Freda E ^a,c   Whyte, Bruce W ^a   Forrest, A Patrick ^a,d   Stewart, Helen J ^a,b  

^a Hawkhead Rd   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d International Medical College   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; FEMALE; HEART INFARCTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTECTOMY; MORBIDITY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; LONG-TERM CARE; MASTECTOMY; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0029096747     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.311.7011.977     Document Type: Article

References (12)

1. McDonald CC Stewart HJ for the Scottish Breast Cancer Committee. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991; 303: 435–7.
2. Scottish Breast Cancer Trials Committee. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987; ii: 171–5.
3. International classification of diseases, ninth revision Geneva: World Health Organisation, 1978.
4. Altman DG de Stavola BL. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994; 13: 301–41.
5. Dewar JA Horobin JM Preece PE Tavendale R Tunstall-Pedoe H Wood RAB. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 1992; 305: 225–6.
6. Cuzick J Allen D Baum M Barrett J Clark G Kakkar V, et al. Long term effects of tamoxifen. Eur J Cancer 1993; 29A: 15–21.
7. Bruning PF Bonfrer JMG Hart AAM de Jong-Bakker M Linders D van Loon J, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 1988; 58: 497–9.
8. Love RR Newcomb PA Wiebe DA Surawicz TS Jordan VC Carbone PP, et al. Effects of tamoxifen therapy in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990; 16: 1327–32.
9. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36–9.
10. Rutqvist LE Mattsson A for the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85: 1398–406.
11. Saphner T Tormey DC Gray R. Venous and arterial thrombosis for patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286–94.
12. Jordan VC Fritz NF Tormey DC. Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res 1987; 47: 4517–9.